Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic treatment of the main clinical features of t...
Enregistré dans:
Auteurs principaux: | Bargiotas P, Konitsiotis S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/748b0b5b4e2c4f8ea983c472fcb6463b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
par: Yang X, et autres
Publié: (2013) -
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
par: Shi H, et autres
Publié: (2015) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
par: David J Brooks
Publié: (2008) -
Treatment of neurolept-induced tardive dyskinesia
par: Jankelowitz SK
Publié: (2013) -
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
par: Wu N, et autres
Publié: (2018)